Objectives: to examined if the estimated glomerular filtration rate (eGFR) slope over a 5-year period has a relationship with incident cardiovascular events in the following 5 years.
Strengths
-a large population with four eGFR measurements in different time periods, representative for the general population was used -data was collected over 10 years
Limitations:
-No proteinuria, smoking and body mass index to use it in the analyses -using a real life data-set means that there is an important loss to follow up due to combination of mortality and change of GP.
Introduction
Loss of kidney function due to advanced age is a normal phenomenon. Changes in glomerular filtration rate (GFR) are a consequence of hemodynamic and structural changes, including loss of renal mass (1) . In the Flemish part of Belgium, the prevalence of CKD is estimated 13% in males and 16% in females (2) .
Only a few patients with CKD will progress to end-stage renal disease, most of them will die of other conditions like cardiovascular disease. Risk factors that contribute to the development of end-stage renal disease are diabetes, high cholesterol, high LDL, hypertension and female gender (3, 4) . However, an eGFR persistently (≥ 3 months) dropping below 60 ml/min/1.73m 2 signifies chronic kidney disease (CKD) and is associated with a higher risk of complications. In CKD patients hospitalization rates are higher and there is an increased risk of cardiovascular disease and death. (5, 6) Rapid decline of kidney function is suggested to cause a higher incidence of cardiovascular events like acute myocardial infarction (AMI), heart failure, stroke (CVA/TIA) and peripheral artery disease (7, 8) . The higher cardiovascular risk in CKD is often under-recognised and undertreated in primary care (9) .
The eGFR slope represents a more dynamic parameter compared to measurements taken at one point (10) (11) (12) (13) . A distinction can be made between stable eGFR (+/-1 ml/min/y) and variable eGFR (+/-3 or +/-5 ml/min/y). Shlipak et al. (8) found in the cardiovascular health study that especially a rapid decline of eGFR, defined as > 3 mL/min/year, sets a higher risk for AMI, heart failure and stroke. An other study (14) reports a similar correlation between eGFR decline and CV events. These studies add further evidence that change in eGFR slope can give a worse cardiovascular outcome. This could be a relevant parameter for automatically generated cardiovascular risk calculations. However before implementing the eGFR slope in risk calculations it's essential to analyse its predictive value in population based data and to analyse the subpopulation who has a strong decline in eGFR over time.
The objective of this study is to determine if the eGFR slope over a 5-year period has a relationship with incident cardiovascular events defined as AMI, peripheral arterial disease, CVA/TIA and acute heart failure in the following 5 years in a Flemish general practice population.
Methods

Setting
The present study is a retrospective data-analysis using the INTEGO databank, which incorporates epidemiological data from more than 100 general practitioners (GPs) residing in the Flemish part of Belgium. In Medidoc®, a medical software program, GPs use a coded registration system based upon validated algorithms (15) . The group of patients that visits at least once the general practice in one year is called the "Yearly Contact Group" or YCG. . With these measurements, we calculated the eGFR slope (ml/min/y) and divided the population into following subgroups: (-1.00,1.00]
(reference group), (-3.00,-1.00], (-5.00,-3.00], ≤ -5.00, (1.00, 3 .00] (3.00,5.00) and ≥ 5.00 ml/min/1.73m 2 per year (ml/min/year). In the case that a patient had several creatinine values in the same semester, we took the mean value of the creatinine. We excluded patients of whom we did not visit their GP after 1/1/2011.
Patient and public involvement
Intego is a long excisting database funded by the Flemish government. Patients or their representatives are not involved in the design of this database or research conducted on it.
Outcome
During the follow-up period, between 1 January 2011 and 31 December 2015, cardiovascular events described as incident acute myocardial infarction (AMI, ICPC2-code K75 and/or K76), Patients who had no contact with the GP in the follow-up period were censored. We considered following variables as potential confounders: age, female gender, diabetes (T90), hypertension (K85, K86), baseline kidney function (last value in 5 year period) and cardiovascular event (codes K75, K76, K77, K89, K90, K92 ) in history. Patients were censored on the data of there last contact during follow up.
Statistical analysis
All analyses were performed using R software. We analysed the slope of eGFR by using the least square method and baseline characteristics are measured on 01/01/2011 (see Table   3 ). Next, Cox proportional hazards model was used to evaluate the association between eGFR slope and the incidence of CV events. Since the Proportional Hazards model assumption held, we further calculated the hazard ratios using three different models. Model 1 was the basic model and adjusted for age and gender. Model 2 was adjusted for age, gender, hypertension, diabetes, and CV event history. Lastly, Model 3 considered in addition one more covariate, namely the baseline kidney function, where we considered the last eGFR measurement before 1/1/2011.
Results
The study population is described in table 1. 19,567 patients met the inclusion criteria and had different eGFR measurements in at least four different time periods. The mean age of this group was 66.1± 11.6 years and 52% (10, 206) were women. We excluded 465 patients since we were not able to track the last time that they visited a general practitioner. Patients with diabetes or hypertension were slightly more likely to be in the groups with a negative eGFR slope. A history of CV events was more common in following groups: ≤ -5 and (-5 to-
3). Table 1 shows also that respectively 86,0 % and 91,9 %of the patients in the group with a slope < -5 and -5 to -3 ml/Min/year has an Egfr >60 Ml/min. Table 2 gives an overview of eGFR slope and CV event during follow-up. Nearly 12% of the patients in the category ≤ -5 and (-5 to -3) had a new CV event compared to 7.8% of the reference group. In the (3 to 5) and ≥ 5 group, a new event occurred only in about 6% of the patients. Figure 1 displays the results of differences in survival time between patients belonging to any of previously defined slope groups. Also, an informative risk set 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   7 10% suffered from cardiovascular event during the length of follow-up. The patients that had a slope ((-1 to 1 ), (1 to 3 ) and (3 to 5 )) had similar survival rates, but worse than those with a slope ≥ 5.00. Next were the patients with slope (-3 to -1), followed by (-5 to -3) and the worst survival rates were those with a slope ≤ -5 . Approximately 15 % of the patients in slope category ≤ -5 had a CV event in comparison to the reference group, where only 10%
had an event.
An overview of the hazards ratios (HR) and 95%-confidence interval per adjusted model stratified to eGFR slope is given in table 3. The HRs of patients with a positive eGFR slope were all insignificant, whereas the HR of the negative eGFR slopes were statistically significant.. Patients that had a slope ≤ -5.00 were 1.55 more likely to develop a CV event compared with those of (-1.00,1.00). Similar interpretations hold for the other groups as well.
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give a subsequent worse cardiovascular outcome in the following 5 years. We found that patients with declining eGFR slope are more at risk to have a cardiovascular event than those with stable or rising eGFR slope. The survival rates of patients with an eGFR slope ≤ -3.00 ml/min/year are worse than the survival rates in other groups. These data suggest that the eGFR slope can be prognostic for cardiovascular health irrespectively of the eGFR itself.
Using this eGFR slope identifies a group af patients with still a normal or slightly decreased eGFR and still higher risk for CV events.
Context of the results
As to cardiovascular disease and eGFR slope, two recent studies with a large study population have been conducted. Naimark et al. (12) found in a large analysis of several existing cohort studies that eGFR changes, positive as well as negative, have a significant association with all-cause mortality, cardiovascular mortality and non-cardiovascular mortality. Turin et al. investigated the association between eGFR change over 2.5 years and the risk of congestive heart failure (CHF), acute myocardial infarction and stroke (16) . Risk of CHF, AMI and stroke was highest when eGFR decline was more than -5 ml/min/y. The adjusted hazard ratios (HR) of CHF, AMI and stroke were respectively 2.57, 1.31 and 1.29.
However, when adjusting for last eGFR measurement, a significant association was only seen with CHF (HR: 1.78).
When we adjusted for the last eGFR measurement, no significant difference in hazard ratio was seen in contrast to the Turin study, which used a shorter time period and only three eGFR measurements. We do not find a U-shape relation between the eGFR slope and cardiovascular events as reported for the eGFR slope an Mortality.
An important finding in this study is that an eGFR slope <-3 ml/min/year over a 5 years time period based on at least 4 Egfr measurement predicts cardiovascular event independent of the EgfR itselfs. Moreover most of these patients with an negative eGFR slope have still an an Egfr above 60 ml/min. So this eGFR slope identifies a risk group that is not identified using the eGFR only.
Strengths and Limitations
The strength of this study is that we used a large population with four eGFR measurements in different time periods, representative for the general population. Another strong point is There are some limitations though; we did not have sufficient information about proteinuria, smoking and body mass index to use it in the analyses without including large bias. Finally, using a real life data-set means that there is an important loss to follow up due to combination of mortality and change of GP.
Recommendations
We think it is useful to imply the eGFR slope into the medical software program and create an alert to warn the GP when a declining eGFR of at least 3 ml/min/year is noticed and therefore is at risk for cardiovascular events. It contributes to the awareness of the GP more than personal intuition can do. The fact that most of the slope category ≤ -5.00 had a normal kidney function at baseline is misleading and therefore deterioration of the eGFR slope can be underestimated if the eGFR slope is not taken into account.
To colcude, there is a correlation between eGFR slope over a five year time period and incident cardiovascular events. Negative eGFR slopes of at least -3.00 ml/min/year give a higher risk of cardiovascular events over a 5-year period than stable slopes or increasing slopes independently of the eGFR at baseline. Further research is needed to see if this deterioration responds to treatment and if so, which treatments or preventive measures should be taken? Will slowing down the process of declining kidney function also diminish the incidence of cardiovascular events? For these reasons, an intervention study is needed that will assess these questions. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 PM extracted the data. GVP, VDAM, PM, BV and GG are responsible for the study concept, design and acquisition of participants and data. All authors participated in the interpretation of the data.
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Abstract
Objectives: to examine if the estimated glomerular filtration rate (eGFR) slope over a 5-year period is related to incident cardiovascular events in the following 5 years.
Design:
Retrospective cohort study
Setting: Primary care
Participants:
All patients aged ≥ 50 years with at least four eGFR measurements between 01/01/2006 and 31/12/2010 were included in the study.
Outcome measures:
During the follow-up period (01/01/2011 until 31/12/2015) cardiovascular events (acute myocardial infarction, stroke (CVA/TIA), peripheral arterial disease and acute heart failure) were identified.
Methods.
The slope was calculated by the least square method (in ml/min/y). The following slope categories were considered: (-1 to 1), (-3 to-1) (-5 to -3], ≤ -5, (1 to 3), (3 to 5) and ≥ 5.00 ml/min/year. Cox proportional hazards model was used to assess the association between eGFR slope and incidence of cardiovascular events. Survival probability from cardiovascular events was estimated per slope category.
Results 19,567 patients had at least four eGFR measurements, of whom 52% was female. 12% of the ≤-5 slope category developed a new cardiovascular event in comparison to 7.8 % of the reference group and 5.4% of the ≥5 slope category. Survival rates were worst in those with a slope ≤-5. Patients with a slope of (-5 to-3) and ≤-5 had an adjusted hazard ratio (HR) of 1.37 and 1.55, respectively. Most patients with a slope < -3 ml/min had an eGFR still > 60ml/min.
Conclusions Negative eGFR slopes of at least 3 ml/min/year give irrespectively of the eGFR itself a higher risk of cardiovascular events compared to patient groups with stable or improved kidney -Proteinuria, smoking status and body mass index were not included in the analyses -Using a real life data-set means that there was an important loss to follow-up due to a combination of mortality and change of GP.
Introduction
Loss of kidney function due to advanced age is a normal phenomenon. Changes in glomerular filtration rate (GFR) are a consequence of hemodynamic and structural changes, including loss of renal mass (1). In the Flemish part of Belgium, the prevalence of CKD is estimated at 13% in men and 16% in women (2) .
Only a few patients with CKD will progress to end-stage renal disease because most of them will die of other causes such as cardiovascular disease. Risk factors that contribute to the development of end-stage renal disease are diabetes, high cholesterol, high LDL, hypertension and female gender (3, 4) . However, an eGFR persistently (≥ 3 months) dropping below 60 ml/min/1.73m 2 signifies chronic kidney disease (CKD) and is associated with a higher risk of complications. In patients with CKD hospitalization rates are higher and they have an increased risk of cardiovascular disease and death. (5, 6) Rapid decline of kidney function is suggested to cause a higher incidence of cardiovascular events such as acute myocardial infarction (AMI), heart failure, stroke (CVA/TIA) and peripheral artery disease (7, 8) . The higher cardiovascular risk in CKD is often underrecognised and undertreated in primary care (9) .
The eGFR slope represents a more dynamic parameter compared to measurements taken at one point (10) (11) (12) (13) . A distinction can be made between stable eGFR (+/-1 ml/min/y) and variable eGFR (+/-3 or +/-5 ml/min/y). In their study on cardiovascular health, Shlipak et al. (8) found that especially a rapid decline of eGFR, defined as > 3 mL/min/year, indicates a higher risk of AMI, heart failure and stroke. An other study (14) reports a similar correlation between eGFR decline and CV events. These studies add further evidence that changes in eGFR slope can give a worse cardiovascular outcome. This could be a relevant parameter for automatically generated cardiovascular risk calculations. However, before implementing the eGFR slope in risk calculations it is essential to analyse its predictive value in population-based data and to analyse the subpopulation that has a strong decline in eGFR over time.
The objective of this study was to determine if the eGFR slope over a 5-year period is related to incident cardiovascular events defined as AMI, peripheral arterial disease, CVA/TIA and acute heart failure in the following 5 years in a Flemish general practice population.
Methods
Setting
The present study is a retrospective data-analysis using the INTEGO databank, which incorporates epidemiological data from more than 100 general practitioners (GPs) residing in the (1.00,3.00] (3.00,5.00) and ≥ 5.00 ml/min/1.73m 2 per year (ml/min/year). In case a patient had several measurements of creatinine values in the same semester, we included the mean value.
We excluded patients of who did not visit their GP after 1/1/2011. 
Patient and public involvement
Statistical analysis
All analyses were performed using R software. We analysed the slope of eGFR by using the leastsquare method and baseline characteristics were measured on 01/01/2011. Next, Cox proportional hazards model was used to evaluate the association between eGFR slope and incidence of CV events. Since the Proportional Hazards model assumption held, we further calculated the hazard ratios using three different models. Model 1 was the basic model and was adjusted for age and gender. Model 2 was adjusted for age, gender, hypertension, diabetes, and CV event history. Lastly, Model 3 in addition considered one more covariate, namely baseline kidney function, where we considered the last eGFR measurement before 1/1/2011.
Results
The study population is described in Table 1 . Inclusion criteria were met by 19,567 patients and had different eGFR measurements in at least four different time periods. The mean age of this group was 66.1± 11.6 years and 52% (10,206) were women. We excluded 465 patients since we
were not able to track the last time that they visited a general practitioner. Patients with diabetes or hypertension were slightly more likely to be in the groups with a negative eGFR slope. A history of CV events was more common in the following groups: ≤ -5 and (-5 to-3). Table 1 also shows that 86,0 % and 91,9 % of the patients in the group with a slope < -5 and -5 to -3 ml/Min/year, respectively had an Egfr >60 Ml/min.
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 2 provides an overview of eGFR slope and CV event during follow-up. Nearly 12% of the patients in the category ≤ -5 and (-5 to -3) had a new CV event compared to 7.8% of the reference group. In the (3 to 5) and ≥ 5 group, a new event occurred only in about 6% of patients. Figure 1 displays the results of differences in survival time between patients belonging to any of previously defined slope groups. Also, an informative risk set table is added, which shows the number of patients that were under observation in the specific period. The risk table is indicative of how many people were available (or at risk) throughout this period. It appeared that those who had a slope ≥ 5 had the best survival rate. Less than 10% suffered from cardiovascular event during the time of follow-up. The patients that had a slope ((-1 to 1 ), (1 to 3 ) and (3 to 5 )) had similar survival rates, but worse than those with a slope ≥ 5.00. Next were the patients with slope (-3 to -1), followed by (-5 to -3) and the worst survival rates were those with a slope ≤ -5 . Approximately 15 % of the patients in slope category ≤ -5 had a CV event in comparison to the reference group, where only 10% had an event.
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Discussion eGFR Slope and Cardiovascular Events: principal findings
We used a large population to examine if a declining eGFR slope over a 5-year period can show subsequent worse cardiovascular outcome in the following 5 years. We found that patients with declining eGFR slope were more at risk of a cardiovascular event than those with stable or rising eGFR slope. The survival rates of patients with an eGFR slope ≤ -3.00 ml/min/year were worse than the survival rates in other groups. These data suggest that the eGFR slope can be prognostic for cardiovascular health irrespective of the eGFR itself. Using eGFR slope can identify a group of patients with a still normal or slightly decreased eGFR and still higher risk for CV events.
Context of the results
As to cardiovascular disease and eGFR slope, two recent studies with a large study population have been conducted. Naimark et al. (12) found in a large analysis of several existing cohort studies that eGFR changes, positive as well as negative, have a significant association with allcause mortality, cardiovascular mortality and non-cardiovascular mortality. Turin et al. investigated the association between eGFR change over 2.5 years and the risk of congestive heart failure (CHF), acute myocardial infarction and stroke (16) . Risk of CHF, AMI and stroke was highest when eGFR decline was more than -5 ml/min/y. The adjusted hazard ratios (HR) of CHF, AMI and stroke were 2.57, 1.31 and 1.29, respectively. However, when adjusting for last eGFR measurement, a significant association was only seen with CHF (HR: 1.78).
When we adjusted for the last eGFR measurement, no significant difference in hazard ratio was seen, in contrast to the Turin study, which used a shorter time period and only three eGFR measurements. We did not find a U-shape relation between the eGFR slope and cardiovascular events as reported for the eGFR slope and mortality.
An important finding in this study is that an eGFR slope <-3 ml/min/year over a 5 years time period based on at least 4 Egfr measurement predicts cardiovascular event independent of the EgfR itself. Moreover, most of our patients with a negative eGFR slope still have l an Egfr above 60 ml/min. Hence, this eGFR slope identifies a risk group that cannot be identified using the eGFR only. The strength of this study is that we used a large population with four eGFR measurements in different time periods, representative of the general population. Another strong point is that we collected these data over 10 years using the first five years as predictor for the next five years.
Strengths and Limitations
Other studies often used a shorter time period for gaining eGFR values or fewer eGFR values to calculate their slope, causing the result to be more sensitive to smaller eGFR variations.
Our study is limited in that we did not have sufficient information about proteinuria, smoking and body mass index to use it in the analyses without resulting in considerable bias. Finally, using a real-life data-set means that there is an important loss to follow-up due to the combination of mortality and change of GP.
Recommendations
We think it is useful to implement the eGFR slope into medical software programmes and create an alert to warn the GP when a declining eGFR of at least 3 ml/min/year is noticed and the patient is thus at risk of cardiovascular events. Implementing such an alert would contribute to the awareness of the GP more than personal intuition can do. The fact that most of the slope category ≤ -5.00 had a normal kidney function at baseline is misleading and therefore deterioration of the eGFR slope can be underestimated if the eGFR slope is not taken into account.
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